Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista Colombiana de Ciencias Químico - Farmacéuticas
versión impresa ISSN 0034-7418versión On-line ISSN 1909-6356
Resumen
TROCHE-CONCEPCION, Yenilen et al. Development of a lyophilized injectable of zoledronic acid 5 mg. Stability study. Rev. colomb. cienc. quim. farm. [online]. 2022, vol.51, n.2, pp.539-556. Epub 29-Mar-2023. ISSN 0034-7418. https://doi.org/10.15446/rcciquifa.v51n2.105101.
Introduction:
Zoledronic acid is an inhibitor of bone resorption used in the treatment of Paget's disease, the prevention of glucocorticoid-induced osteoporosis, osteoporosis in postmenopausal women and in men.
Aim:
To evaluate the stability of a new lyophilized injection of zoledronic acid 5 mg through the quality parameters.
Methods:
An HPLC method with UV detector was validated for the finished product and the chemical stability of the formulation was determined through the presence of degradation products and the concentration of zoledronic acid in the finished product. In addition, the organoleptic characteristics, pH, sterility and bacterial endotoxins, particles in injectables and totality and transparency of solutions were measured.
Results:
The chromatographic method was satisfactory for its use in the evaluation of the finished product. 3 batches of the lyophilized 5 mg zoledronic acid injection were made which met the quality limits established during 6 months (accelerated stability) and up to 24 months (shelf life).
Palabras clave : Zoledronic acid; quality attributes; validation; stability.